Leung A C, Henderson I S, Halls D J, Dobbie J W
Br Med J (Clin Res Ed). 1983 Apr 30;286(6375):1379-81. doi: 10.1136/bmj.286.6375.1379.
In an attempt to discover a phosphate binding agent for use in uraemia that would not lead to appreciable systemic absorption of aluminium the effect of sucralfate was evaluated after three weeks and compared with that of the existing standard agent aluminium hydroxide. Sucralfate caused a decrease in serum phosphate concentration comparable with that obtained with aluminium hydroxide, but similar absorption of aluminium resulted. Sucralfate may be the phosphate binder of choice in patients with uraemia and peptic ulceration; care should be taken in using large doses of the drug in patients with normal renal function.
为了找到一种用于尿毒症的不会导致铝大量全身吸收的磷酸盐结合剂，在三周后评估了硫糖铝的效果，并与现有的标准制剂氢氧化铝进行了比较。硫糖铝使血清磷酸盐浓度降低的程度与氢氧化铝相当，但铝的吸收情况相似。硫糖铝可能是尿毒症合并消化性溃疡患者的首选磷酸盐结合剂；肾功能正常的患者使用大剂量该药物时应谨慎。
